以HPV为对象的T细胞治疗,治愈了病人的晚期癌症,有些患者多年来没有癌症。 T cell therapy targeting HPV cured advanced cancers in patients, with some remaining cancer-free for years.

Rutgers癌症研究所和RWJBarnabas健康协会在国家癌症研究所的支持下进行的一项具有里程碑意义的研究显示,针对HPV抗原的T细胞疗法使与HPV有关的癌症患者,包括头部和颈部、宫颈癌和肛门癌,得以持续完全康复。 A landmark study by Rutgers Cancer Institute and RWJBarnabas Health, supported by the National Cancer Institute, reveals that T cell therapies targeting HPV antigens led to sustained complete remissions in patients with HPV-related cancers, including head and neck, cervical, and anal cancers. 临床试验于2025年11月7日宣布, 发现一些病人在接受治疗后几年内仍没有癌症, Announced on November 7, 2025, the clinical trial found that some patients remained cancer-free for several years after treatment, even following prior standard therapies. 结果表明,经过工程改造的T细胞能够有效地重新激活免疫系统来长期控制癌症,标志着病毒引起的恶性肿瘤的免疫疗法取得了显著进展。 The results suggest engineered T cells can effectively re-engage the immune system to control cancer long-term, marking a significant advance in immunotherapy for virus-driven malignancies.